Intravitreal Bevacizumab for the Treatment of Retinal Neovascularization Secondary to Ocular Toxoplasmosis

Our aim was to present a case of ocular toxoplasmosis with retinal neovascularization treated with intravitreal bevacizumab. A 21-year-old healthy man had admitted to our Eye Clinic with complaints of floaters and blurred vision in the right eye (OD);For one year. On examination, visual acuity was 20/200 in the right eye and 200/200 in the left eye (OS). A few active inflammatory cells were seen in the vitreous (1+ cell), and a high IgG anti-Toxoplasmosis titer was detected. Fundus examination revealed bilateral chorioretinal scars in posterior poles and peripheral retinal neovascularization in the superotemporal region of the right eye. After administration of intravitreal bevacizumab (1.25 mg in 0.05 ml OD) the peripheral retinal neovascularization regressed. In summary, intravitreal bevacizumab may be an effective alternative option in the management of retinal neovascularization secondary to ocular toxoplasmosis.